More Articles Back to Article
Tocilizumab might improve survival in severe COVID-19
Preliminary data from a study involving 239 COVID-19 patients during the pandemic's early weeks suggest treatment with the cancer drug tocilizumab could improve survival among patients on mechanical ventilators. The survival rate was 75% for those on ventilators who were treated with the drug, compared with survival rates of 10% to 50% reported elsewhere, according to study author Dr. Christina Price, chief of clinical allergy and clinical immunology at Yale New Haven Hospital in Connecticut. HealthDay News (6/23)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!